Login
- A -
Austria- B -
Belgium- D -
Denmark- F -
FinlandFrance
- G -
GermanyGreece
- I -
Ireland (Eire)Italy
- N -
NetherlandsNorway
- P -
Portugal- S -
SpainSweden
Switzerland
- U -
United Kingdom
Population (2005)
10.66m
GDP (2004 - PPP basis)
$226.4bn
Health expenditure (2003)
Health expenditure as proportion of GDP (2003)
Size of pharmaceutical market (2003)
Proportion of GDP spent on pharmaceuticals (2002)
Pharmaceuticals as proportion of health expenditure (2002)
Pharmaceutical market growth rate
Local currency
Euro (€)
Summary: Greece
The Greek pharmaceutical market is characterised by some of the lowest prices anywhere in Europe due to comparative price setting policies. The impact of Greece’s low prices is a domination of imported products and very low generics penetration as well as a high level of parallel trade. A positive reimbursement list is re-issued by the authority periodically but November 2004 reforms abolished this list.
Summary of report content
- Summary
- How is the healthcare system structured?
- What size is the pharmaceutical market?
- Are pharmaceuticals taxed?
- How are drug prices set?
- How are prices changed?
- How are drugs reimbursed?
- Is there a payback arrangement?
- Are hospital sales controlled?
- Are OTC prices regulated?
- How are pharmaceutical costs controlled?
- How are generic drugs priced?
- What are wholesale/pharmacy margins?
- Is parallel trade influential?
- What to look out for
- Glossary
- Useful Contacts
Your Basket
Your basket is currently empty.
Search News
News
31/05/2005
European Court ruling disappoints industry and parallel traders
21/01/2005
Drug pricing unconstitutional, rules High Court
30/11/2004
Bar code labelling system to come in force
Related Items